Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

What Is Pinealon? Glu-Asp-Arg Identity and Laboratory Documentation

A research-use identity note on Pinealon as the Glu-Asp-Arg (EDR) tripeptide, with attributed review and mouse-model findings and lot documentation.

What Is Pinealon? Glu-Asp-Arg Identity and Laboratory Documentation

Pinealon is the Glu-Asp-Arg tripeptide evaluated in neuroscience, stress-response, and gerontology research models. The original overview of this page asks three questions: the Glu-Asp-Arg tripeptide sequence, neuroscience and cellular-stress model design, and orthogonal identity and purity checks.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.

The Glu-Asp-Arg tripeptide sequence

Khavinson, Linkova, Kozhevnikova, and Trofimova identified the EDR peptide as Glu-Asp-Arg and reviewed prior reports of neuroprotective properties (Khavinson et al., 2020). The 2021 systematic review maps the name Pinealon to that EDR sequence (Khavinson et al., 2021, Molecules). EDR is not KE (Vilon) and is not KED (Vesugen). A class overview is at What Are Bioregulator Peptides?.

Neuroscience and cellular-stress model design

In the 2020 review, the authors stated that the EDR peptide had been reported to activate gene expression and synthesis of proteins involved in maintaining neuronal functional activity and to reduce the intensity of apoptosis in in-vitro and in-vivo studies; to interfere with the elimination of dendritic spines in neuronal cultures obtained from mice with Alzheimer’s and Huntington’s disease models; and to promote activation of antioxidant-enzyme synthesis in rat cerebellar neuron cultures (Khavinson et al., 2020). Those statements are the review authors’ summary of earlier work. The same review also alludes to behavioral observations in animal studies and to memory findings in elderly patients; those allusions are not adopted here as a treatment claim or as a use instruction.

Khavinson, Ilina, Kraskovskaya, and colleagues later reported that EDR, together with KED, prevented dendritic spine loss in 5xFAD-M mice (Khavinson et al., 2021, Pharmaceuticals). That is a mouse-model observation. This draft does not transcribe dose, route, or schedule from that paper as a regimen, and it does not treat a dendritic-spine finding as a clinical outcome.

Orthogonal identity and purity checks

A tripeptide needs methods suited to low mass, including identity, purity, content, and lot matching. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, and lot traceability apply independently to this row.

Pinealon was not found as a standalone published item in Velnacor’s current research-material catalog listing used for this draft. Use the product directory and the COA Library, then confirm whether a current SKU exists and which lot documents apply in the inquiry. For packing at supply scale, see wholesale peptides.

Cellular-stress and neuroscience models should be named by the system actually used—neuron culture, cerebellar culture, or a transgenic mouse line—rather than by the historical class name alone. Review language that proposes binding or signaling mechanisms is hypothesis-level synthesis in the cited article; it is not restated here as a completed mechanism. Orthogonal identity and purity checks still apply to the Glu-Asp-Arg tripeptide on the bench, independently of that mechanistic discussion.

Selected published literature

  1. Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer’s disease. Molecules. 2020;26(1):159. doi:10.3390/molecules26010159. PubMed 33396470. Review article; cited for EDR identity and the authors’ summary of prior reports, not as a use instruction.
  2. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053. PubMed 34834147. Open access: PMC8619776. Systematic review; cited for the EDR/Pinealon name mapping.
  3. Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective effects of tripeptides—epigenetic regulators in mouse model of Alzheimer’s disease. Pharmaceuticals. 2021;14(6):515. doi:10.3390/ph14060515. PubMed 34071923. Cited for attributed 5xFAD mouse-model observations; dose and route in the paper are not restated here as instructions.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0